Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.